ArticleBJR open2025
The effects of anti-PD-1 therapy on programmed death-ligand 1 expression and glucose metabolism of normal organs in patients with advanced non-small cell lung cancer.
Article in BJR open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04436406 (Measurement of PD-L1 Expression in Cancer to Monitor Treatment Response.), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Measurement of PD-L1 Expression in Cancer to Monitor Treatment Response.
Who cites it
1 citing paper in PubMed.
- Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.Molecular imaging and biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate how anti-PD-1 treatment affects both Programmed Death-Ligand 1 (PD-L1) expression and glucose metabolism within normal tissues of advanced non-small cell lung cancer (NSCLC) patients using a dual SPECT/CT and PET/CT imaging approach. Methods: Ten advanced NSCLC patients (NCT04436406) undergoing anti-PD-1 therapy ± chemotherapy underwent imaging at baseline and 9 weeks. PD-L1 expression was measured using [ Results: No significant changes in SUVs, indicating PD-L1 expression and glucose metabolism, were detected in normal organs after 9 weeks of treatment (all Conclusions: Our study showed stable PD-L1 expression and glucose metabolism within normal organs in advanced NSCLC patients treated with anti-PD-1 therapy ± chemotherapy. Interobserver reliability between observers was excellent. Additional studies with larger patient groups and a specific focus on irAE cases are needed. Advances in knowledge: Through a dual-modality molecular imaging approach, this research provides novel insight into anti-PD-1 therapy's effects on PD-L1 expression and glucose metabolism in normal organs of NSCLC patients, demonstrating that these parameters remain stable post-treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.